Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02439320 · ClinicalTrials.gov registry record · Phase 3
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,231
- Enrollment target
NCT02439320: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT02439320 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 2,231 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (189% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02439320, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,231 participants
- Enrollment target
Study Summary
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
Primary Outcome
The percentage of participants defined as mild, moderate, or severe headache pain becoming none.
Interventions
- DRUG Lasmiditan 100 mg
- DRUG Lasmiditan 200 mg
- DRUG Placebo (matches lasmiditan doses)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,231 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-08 |
| Phase | Phase 3 |
What the finished NCT02439320 record still lists
NCT02439320 is an interventional study that assigns participants to a tested intervention. Its 2,231 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (189% higher).
The record links to 0 conditions, and to 3 interventions - of which Lasmiditan 100 mg is the first listed.
NCT02439320 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02439320 about?
NCT02439320 is a clinical study titled "Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:". This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
What is the current status of trial NCT02439320?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,231 participants. The study started on 2015-04. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02439320?
The interventions under investigation include: Lasmiditan 100 mg (DRUG), Lasmiditan 200 mg (DRUG), Placebo (matches lasmiditan doses) (DRUG).
Who is sponsoring clinical trial NCT02439320?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02439320's enrollment target sits among peer trials
2,231 95th of 2000 higher than 1,906 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06831929 · 2,232 participants · NA
HPV Ends Here: Increasing Uptake of the HPV Vaccine
- NCT06939803 · 2,236 participants · NA
AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.
- NCT04889872 · 2,250 participants · NA
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
- NCT06805513 · 2,250 participants · Phase 3
Actual Use Trial of Tadalafil 5 mg
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia